Jean(Hoffman)Hoffman-CensitsMD

PubMed

• 2628 citations
  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-a...
  Jonathan E. Rosenberg, Jean H. Hoffman-Censits, Thomas Powles, Michiel S. van der Heijden, Arjun Vasant Balar
  Lancet. 2016-05-07
• 199 citations
  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
  Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard
  The Lancet. Oncology. 2021-04-01
• 53 citations
  Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
  Benjamin Miron, Jean H. Hoffman-Censits, Fern Anari, John O'Neill, Daniel M. Geynisman
  European Urology Oncology. 2020-03-10

Journal Articles

• Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies  
  Dan TD, Eldredge-Hindy HB, Hoffman-Censits, J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB, Am J Clin Oncol, 1/25/2015
• An Open Label Randomized Phase II Study Of Pasireotide With And Without Everolimus In Castrate-Resistant Chemotherapy-Naïve Prostate Cancer Patients  
  J. Lin, J. Hoffman-Censits, Journal of Cancer Treatment Communications, 1/1/2015
• Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder Cancer  
  Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, V..., Eur Urol, 1/1/2015
• Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma  
  Hoffman-Censits, J. and Wong, Y, Clin Genitourin Cancer, 1/1/2015
• Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results o...  
  Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, ..., Journal of Clinical Oncology, 6/20/2014
• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy  
  Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K,..., Cancer Cell, 2/10/2014
• A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA  
  Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci M..., Am J Cancer Ther Pharmacol, 1/1/2014
• Practical Approach to the use of Enzalutamide  
  Jean Hoffman-Censits and William Kevin Kelly, Canadian Journal of Urology, 1/1/2014
• Accelerated methotrexate, vinblastine, doxorubicin and cisplatin (AMVAC) is safe, effective and efficient neoadjuvant treatment for muscle invasive bladder cancer: Res...  
  Elizabeth R. Plimack, Jean H. Hoffman-Censits, Rosalia Viterbo, Edouard J. Trabulsi, Eric A. Ross, Richard E. Greenberg, David Chen, Costas D. Lallas, Yu-Ning Wong, Ji..., Journal of Clinical Oncology, 1/1/2014
• Critical Analysis of Contemporary Clinical Research in Muscle-Invasive and Metastatic Urothelial Cancer: A Report from the Bladder Cancer Advocacy Network Clinical Tri...  
  Matthew D. Galsky MD, Ryan Hendricks BS, Robert Svatek MD, Rick Bangs BA, Jean Hoffman-Censits MD, Jessica Clement MD, Robert Dreicer MD, Elizabeth Guancial MD, Noah H..., Cancer, 1/1/2013
• Enzalutamide: A Novel Anti-Androgen for Patients with Castrate-Resistant Prostate Cancer  
  Jean Hoffman-Censits and Wm Kevin Kelly, Clin Cancer Res, 1/1/2013
• Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer?  
  Hoffman-Censits J, Fu M, Seminars in Oncology, 1/1/2013
• Physician Beliefs and Practices for Adjuvant and Salvage Radiation Therapy After Prostatectomy  
  Showalter TN, Ohri N, Teti KG, Foley KS, Keith SW, Trabulsi EJ, Lallas CD, Dicker AP, Hoffman-Censits J, Pizzi LT, Gomella LG, International Journal of Radiation Oncology, Biology, Physics, 1/21/2011
• Chemotherapy for Penile and Urethral Carcinoma  
  Trabulsi, EJ and Hoffman-Censits, J, Urology Clinical of North America, 1/1/2010
• Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience  
  Gomella LG, Lin J, Hoffman-Censits J, Dugan P, Guiles F, Lallas CD, Singh J, McCue P, Showalter T, Valicenti RK, Dicker A, Trabulsi EJ, Journal of Oncology Practice, 1/1/2010
• What’s the “Take Home” Series, Pearls from Clinical Cases: A middle aged woman with MI, stroke and DVT  
  Hoffman-Censits, J and Rubin, RN, Consultant, 1/1/2008
• An integrated genetic linkage map with 1,137 markers constructed from five F2 crosses of autoimmune disease prone and resistant inbred rat strains  
  Dracheva, SV, Remmers, EF, Chen S, Chang L, Gulko, P, Kawahito, Y, Longman, RE, Wang, J, Du, Y, Shepard, J, Ge, L, Joe, B, Kotake, S, Salstrom, JL, Furuya, T, Hoffman,..., Genomics, 1/15/2000
• Fas-deficient lpr mice are more susceptible to graft-versus- host disease  
  Van den Brink, MR, Moore E, Horndasch, KJ, Crawford JM, Hoffman J, Murphy GF, Burakoff, SJ, Journal of Immunology, 1/1/2000
• Localization in rats of genetic loci regulating susceptibility to experimental erosive arthritis and related autoimmune diseases  
  Wilder, RL, Griffiths, MM, Remmers, EF, Cannon, GW, Caspi, RR, Kawahito, Y, Gulko, PS, Longman, RE, Dracheva, SV, Du, Y, Sun, SH, Wang, J, Shepard, JS, Joe, B.Ge, L, C..., Transplantation Proceedings, 1/1/1999
• A genetic linkage map of rat chromosome 20 derived from five F2 crosses  
  Kawahito, Y, Remmers, EF, Wilder, RL, Longman, RE, Gulko, PS Wang, J, Chen, S, Chang, L, Dracheva, S, Ge, L, Hoffman, JH, Shepard, J, Cannon, GW, Griffiths, MM, Immunogenetics, 1/1/1998
• Does differential neuroendocrine control of cytokine production govern the expression of autoimmune diseases in pregnancy and the postpartum period?  
  Elenkov IJ, Hoffman J, Wilder RL, Molecular Medicine Today, 1/1/1997
• Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles  
  Haseley LA, Wisnieski JJ, Denburg MR, Michael-Grossman AR, Ginzler EM,Gourley MF, Hoffman JH, Kimberly RP, Salmon JE, Kidney International, 1/1/1997
• Repeated isolation in the neonatal rat produces alterations in behavior and ventral striatal dopamine release in the juvenile after amphetamine challenge  
  Kehoe P, Shoemaker WJ, Triano L, Hoffman J, Arons C, Behavioral Neuroscience, 1/1/1996
• Neonatal isolation enhances hippocampal dentate response to tetanization in freely-moving juvenile male rats  
  Kehoe, P, Hoffman, JH, Ausin-LaFrance, RJ, Bronzino, JD, Experimental Neurology, 1/1/1995
• Join now to see all

Books/Book Chapters

• The 5-Minute Urology Consult 
  Chapter: Bladder Cancer, Urothelial Urothelial, Metastatic (N+,M+). 
  Jean Hoffman Censits and William K KellyEditors: Leonard Gomella, M.D..Lippincott Williams and WilkinsEdition 3rd,2015
• The 5-Minute Urology Consult 
  Chapter: Bladder Cancer, Urothelial, Muscle Invasive (T2/3/4) Neoadjuvant Therapy. 
  Jean Hoffman Censits and William K KellyEditors: Leonard Gomella, M.D..Lippincott Williams and WilkinsEdition 3rd,2015
• Textbook of Upper Urinary Tract Urothelial Carcinoma 
  Chapter: Systemic Chemotherapy for Upper Tract Urothelial Cancer. 
  Jean Hoffman-CensitsEditors: Michael Grasso and Demetrius Bagley.Springer Publishing2015
• Atlas of Adult Physical Diagnosis 
  Dale Berg and Katherine Worzala, (J. Hoffman-Censits, contributing author)Lippincott Williams and Wilkins2006
• Join now to see all

Abstracts/Posters

• Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a multicenter Phase II study (IMvigor 210).
  Jonathan E. Rosenberg, Daniel P. Petrylak, Oyewale Abidoye, Michiel van Der Heijden, Jean Hoffman-Censits, Andrea Necchi, Peter O'Donnell, Ani Balmanoukian, Yohann Lor..., European Cancer Congress, 1/1/2015
• The First Report of RTOG 0622: A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer...
  R. Valicenti, S. Pugh, E. Trabulsi, O. Sartor, M. Girvigian, S. Rosenthal, S. Williams, J. Hoffman-Censits, J. Schallenkamp, H. Sandler, ASTRO, 1/1/2015
• Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.
  Plimack ER, Dunbrack R, Brennan T, Andrake M, Zhou Y, Serebriiskii I, Dulaimi E, Hoffman-Censits J, Bilusic M, Wong Y, Kutikov A, Viterbo R, Greenberg RE, Chen D, Lall..., ASCO GU Meeting Abstracts, 1/1/2015
• Phase I trial of weekly cabazitaxel with concurrent intensity-modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk ...
  Jianqing Lin, Robert Benjamin Den, Timothy Norman Showalter, Jean H. Hoffman-Censits, Monica McGuire, Brooke Kennedy, Mark Hurwitz, Edouard John Trabulsi, Costas D. La..., ASCO GU Meeting Abstracts, 1/1/2015
• Neoadjuvant chemotherapy (NAC) has no adverse effect on radical cystectomy (RC) or perioperative complications.
  Haseebuddin,M., Mehrazin, R., Trabulsi, E., Devarajan, K., Wong, Y., Hoffman-Censits, J., Lallas, C., Viterbo, R., Kutikov, A., Smaldone, M., Greenberg, R., Uzzo, R...., Journal of Urology; Society of Urologic Oncology Meeting Abstracts, 1/1/2015
• Reducing Decisional Conflict about Treatment Options for Men with Low-Risk, Early Stage Prostate Cancer.
  Leader AE, Petrich A, Quinn AM, Hoffman-Censits J, Trabulsi E, Gomella L, Lallas C, Dicker A, Den R, Daskalakis C, Cocroft J, Myers RE, 35th Annual Meeting of the Society for Behavioral Medicine, Philadelphia, PA, 1/26/2014
• A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy.
  Jean Hoffman-Censits, David J Vaughn, Jianqing Lin, Stephen Michael Keefe, Naomi B Haas, William Kevin Kelly, Terry Hyslop, Monica McGuire, Janelle Robinson, Kattie Kh..., ASCO Meeting Abstracts, 1/1/2014
• Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic ...
  Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean ..., ASCO GU Symposium, 1/1/2014
• Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma.
  Jean H. Hoffman-Censits, Edouard John Trabulsi, David Y. T. Chen, Alexander Kutikov, Jianqing Lin, Rosalia Viterbo, Gary R. Hudes, Kelly A. Healy, Scott Hubosky, Yu-Ni..., ASCO GU Symposium, 1/1/2014
• A Phase II Randomized Open Label Trial of DN24-02: Updated Analysis of HER2 Expression, Immune Responses, Product Parameters and Safety in Patients with Surgically Res...
  Bajorin D, Sharma P, Gomella LG, Plimack E, O’Donnell PH, Hoffman-Censits J, Flaig TW, Quinn D, Sims R, Locker M, Sheikh N, DeVries T, Lerner S. NeuACT, ASCO GU Symposium, 1/1/2014
• Preliminary product parameter and safety results from neuact, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial c...
  Dean F. Bajorin, Leonard G. Gomella, Padmanee Sharma, Elizabeth R. Plimack, Peter H. O'Donnell, Jean H. Hoffman-Censits, Thomas W. Flaig, David I. Quinn, Dwayne Campog..., ASCO, 1/1/2014
• Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DDGC) in patients (pts) with muscle invasive bladder cancer (MIBC): Final results of a multicenter phase II study.
  Elizabeth R. Plimack, Jean Hoffman-Censits, Richard E. Greenberg, Marijo Bilusic, David Y. T. Chen, Yu-Ning Wong, Rosalia Viterbo, Costas Lallas, Jianqing Lin, Edouard..., ASCO, 1/1/2014
• Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadj...
  Elizabeth R. Plimack, Roland Dunbrack Jr., Timothy Brennan, Qiong Wei, Roman Yelensky, Ilya Serebriiskii, Jean H. Hoffman-Censits, Alexander Kutikov, R. Katherine Alpa..., ASCO, 1/1/2014
• The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial can...
  Toni K. Choueiri, Noah M. Hahn, Sumanta Kumar Pal, Ajjai Shivaram Alva, Robert Dreicer, Alexander Starodub, Guru Sonpavde, Jean H. Hoffman-Censits, Joel Picus, Arjun V..., ASCO, 1/1/2014
• A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).
  Andrea Borghese Apolo, Howard L. Parnes, Ravi Amrit Madan, James L. Gulley, John Joseph Wright, Jean H. Hoffman-Censits, Nancy Ann Dawson, Jane B. Trepel, Kattie Khada..., ASCO GU Symposium, 1/1/2014
• Decision counseling about active surveillance and active treatment for early stage, low risk prostate cancer patients.
  Petrich A, Quinn AM, Leader AE, Hoffman-Censits J, Trabulsi E, Gomella L, Lallas C, Dicker A, Den R, Daskalakis C, Cocroft J, Myers RE, 35th Annual North American Meeting of the Society for Medical Decision Making, Baltimore, MD, 1/23/2013
• Phase I/II Clinical Trial of ALT-801, a T-Cell Receptor/IL-2 Fusion Protein, Plus Gemcitabine and Cisplatin in Urothelial Cancer.
  Mayer N. Fishman, Julio Hadjenberg, Timothy Kuzel, Amit Mahipal, Charles Joel Rosser, Danny Landau, Shilpa Gupta, Daniel A. Vaena, Sanjiv S. Agarwala, John Francis Mah..., GU ASCO Annual Meeting, 1/1/2013
• Lallas, Katherine Burns, Edouard John Trabuls, Ronald Myers. Impact of a novel decision counseling program© on treatment knowledge, decisional conflict and choice in m...
  Jean H. Hoffman-Censits, Anett Petrich, Anna Quinn, Amy Leader, Leonard G. Gomella, Adam Dicker, Robert Benjamin Den, Mark Hurwitz, William Kevin Kelly, Costas D, ASCO Quality Care Symposium, 1/1/2013
• Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (...
  Michael F. Press, Peter H. O'Donnell, Elizabeth R. Plimack, Jean H. Hoffman-Censits, David I. Quinn, Padmanee Sharma, Todd DeVries, Melissa Chen, Michael Locker, Dean ..., ASCO Annual Meeting, 1/1/2013
• A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.
  Jianqing Lin, Jean H. Hoffman-Censits, Danielle Duffy, Inna Chervoneva, Deborah Kilpatrick, Brooke Kennedy, Edouard John Trabulsi, Costas D. Lallas, Leonard G. Gomella..., ASCO Annual Meeting, 1/1/2013
• Multidisciplinary management and use of neoadjuvant cisplatin combination chemotherapy in patients with muscle-invasive urothelial bladder cancer
  Jean H. Hoffman-Censits, Jianqing Lin, Costas D. Lallas, Timothy Norman Showalter, Robert Benjamin Den, Ellen Doubet, Jillian Brown, Jaspreet Singh, Adam Dicker, Leona..., ASCO Annual Meeting, 1/1/2012
• Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study.
  ER. Plimack, JH Hoffman-Censits, R Viterbo, RE Greenberg, D Chen, C Lallas, EJ Trabulsi, Y Wong, A Kutikov, J Lin, G Duncan, BA, C Cione, C O'Sullivan, D Kilpatrick, E..., ASCO Annual Meeting, 1/1/2012
• Neoadjuvant Accelerated MVAC in Patients with Muscle Invasive Bladder Cancer: a Multi-Institutional Prospectively Accrued Cohort.
  R. Mehrazin, E. R. Plimack, A. Kutikov, J. H. Hoffman-Censits, R. Viterbo, R. E. Greenberg, C. D. Lallas, E. J. Trabulsi, Y-N Wong, S. A. Boorjian, R. G. Uzzo, D. Y. T..., Society of Urologic Oncology (SUO) Annual Meeting, 1/1/2012
• Dose intensity of cisplatin and gemcitabine (CG) for muscle invasive urothelial bladder cancer (MIUBC) in the neoadjuvant versus adjuvant settings:The Fox Chase Cancer...
  J Hoffman-Censits, Y Wong, T Li, S Boorjian, VN Giri, R Uzzo, RE Greenberg, G Hudes and D Chen, ASCO Annual Meeting, 1/1/2009
• Neonatal Isolation Enhances Hippocampal LTP in Freely Moving Juvenile Rats.
  Kehoe, P, Hoffman, JH, Ausin-LaFrance, RJ, Bronzino, JD, Society for Neuroscience, 1/1/1994
• Join now to see all

Lectures

• Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Update on Clinical Trials in Urothelial Carcinomas 
  King of Prussia, PA - 1/1/2015
• Testis Cancer Treatment with focus on stage I disease 
  1/1/2015
• Management of Bladder and Upper Tract Urothelial Cancers 
  1/1/2015
• Efficacy and Safety Results From a Pivotal Multicenter Phase II Study (IMvigor 210) of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcino... 
  Washington, DC - 1/1/2015
• Neoadjuvant Treatment: Standard of Care? 
  Washington, DC - 1/1/2015
• Treatment of locally advanced and metastatic urothelial cancer. 
  Pocono Medical Center, E Stroudsburg, PA - 1/1/2015
• Update on Clinical Trials 
  Philadelphia, PA - 1/1/2015
• Staging and Management of Bladder Cancer 
  Philadelphia, PA - 1/1/2015
• Bladder Cancer – evolving paradigms and immunotherapy. 
  Albert Einstein Medical Center, Philadelphia, PA - 1/1/2015
• ASCO 2015 Update – genitourinary malignancies. 
  Lafayette Hill, PA - 1/1/2015
• Bladder Cancer – evolving paradigms in treatment 
  Nazareth Hospital, Philadelphia, PA - 1/1/2015
• Testis Cancer Treatment with focus on stage I disease. 
  Thomas Jefferson University - 1/1/2014
• Urothelial cancer management. 
  Thomas Jefferson University - 1/1/2014
• Truth-telling in Oncology and Clinical Trial Ethics 
  Thomas Jefferson University - 1/1/2014
• Management of Locally Advanced Urothelial Cancer: Entering the Targeted Era 
  Thomas Jefferson University Hospital, Philadelphia, PA - 1/1/2014
• Urothelial Cancer – Management update with review of current and pending cooperative group clinical trials. 
  Orlando, FL - 1/1/2014
• Management of locally advanced an metastatic urothelial cancer in the molecular age. 
  Wynewood, PA - 1/1/2014
• Navigating the BCAN Clinical Trials Dashboard 
  1/1/2014
• Neoadjuvant chemotherapy versus risk stratification and adjuvant chemotherapy for urothelial bladder cancer. 
  Philadelphia, PA - 1/1/2014
• Update on Bladder Cancer – BCAN WALK introductory remarks. 
  Philadelphia, PA - 1/1/2014
• Advanced Prostate Cancer – treatment update and trial horizons. 
  Philadelphia, PA - 1/1/2014
• The Basics of Kidney Cancer and Targeted Therapy 
  Philadelphia, PA - 1/1/2014
• Urothelial Cancer: Basics, Management, and Opportunities for Translational Research. 
  Philadelphia, PA - 1/1/2013
• Gentitourinary Malignancies: Updates in Therapy 
  Philadelphia, PA - 1/1/2013
• Join now to see all